The immune response of rats to vaccination with the cDNA or protein forms of the cysteine proteinase of Fasciola hepatica.
Our previous experiments have shown that intramuscular injection of Sprague-Dawley rats with a pcDNA 3.1 vector carrying cDNA encoding for a cysteine proteinase (CP) of F. hepatica may induce a high level of protection against subsequent infection with F. hepatica metacercariae (mc). The aim of the present study is to compare the immune response of Sprague-Dawley rats vaccinated intranasally with plasmid containing cDNA of CP of the fluke and intramuscularly or intraperitoneally with the recombinated enzyme protein to challenge with fluke metacercariae. In addition, protection following intranasal DNA vaccination was evaluated. Two experiments were carried out. In the first experiment rats were vaccinated twice with 50microg of cDNA containing plasmid or with 100microg protein of recombinated CP. Three weeks after the second vaccination rats were challenged orally with 25 mc. On days 0, 21, 42 and 63 after the challenge blood samples were collected for the evaluation of white blood cell, eosinophil and specific antibody responses. During the second experiment groups of five male and female rats were vaccinated twice intranasally with CPcDNA then challenged with 30 mc and dissected 5 weeks later. Results obtained in the experiments suggested that intranasal immunisation of rats with CPcDNA seems to favour a Th2 regulated antibody response. Intramuscular or intraperitoneal injections of CP protein stimulate both Th1 and Th2-dependent antibodies. Mean worm burdens found in rats vaccinated intranasally 5 or 10 weeks after the challenge were reduced by 61-75% in comparison with the challenge controls which suggests that intranasal vaccination with CPcDNA may protect hosts against F. hepatica infection.
Wedrychowicz
H
H
W. Stefanski Institute of Parasitology PAS, Twarda 51/55, 00-818 Warsaw, Poland. halinwe@twarda.pan.pl
Lamparska
M
M
Kesik
M
M
Kotomski
G
G
Mieszczanek
J
J
Jedlina-Panasiuk
L
L
Płucienniczak
A
A
D000818:Animals; D000909:Antibodies, Helminth / Q000276:immunology; D003546:Cysteine Endopeptidases / Q000235:genetics* / Q000276:immunology*; D018076:DNA, Complementary / Q000235:genetics; D018509:DNA, Helminth / Q000276:immunology*; D004804:Eosinophils / Q000276:immunology; D005210:Fasciola hepatica / Q000276:immunology*; D005211:Fascioliasis / Q000276:immunology*; D007962:Leukocytes / Q000276:immunology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology*; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology
D000909:Antibodies, Helminth; D018076:DNA, Complementary; D018509:DNA, Helminth; D014612:Vaccines; D019444:Vaccines, DNA; D003546:Cysteine Endopeptidases